Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Biologics in severe asthma: the overlap endotype - opportunities and challenges
Agamemnon Bakakos, Stelios Loukides, Omar S. Usmani, et al.
Expert Opinion on Biological Therapy (2020) Vol. 20, Iss. 12, pp. 1427-1434
Closed Access | Times Cited: 20

Showing 20 citing articles:

Phenotyping of Severe Asthma in the Era of Broad-Acting Anti-Asthma Biologics
Arnaud Bourdin, Guy Brusselle, Simon Couillard, et al.
The Journal of Allergy and Clinical Immunology In Practice (2024) Vol. 12, Iss. 4, pp. 809-823
Open Access | Times Cited: 10
Biomarkers for Severe Asthma: Lessons From Longitudinal Cohort Studies
Young‐Soo Lee, Quang Luu Quoc, Hae‐Sim Park
Allergy Asthma and Immunology Research (2021) Vol. 13, Iss. 3, pp. 375-375
Open Access | Times Cited: 49
Effective Management of Severe Asthma with Biologic Medications in Adult Patients: A Literature Review and International Expert Opinion
Roland Buhl, Elisabeth H. Bel, Arnaud Bourdin, et al.
The Journal of Allergy and Clinical Immunology In Practice (2021) Vol. 10, Iss. 2, pp. 422-432
Open Access | Times Cited: 45
Monoclonal antibodies in the management of asthma: Dead ends, current status and future perspectives
Grzegorz Kardas, Michał Panek, Piotr Kuna, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 31
Real-World Biologic Use Patterns in Severe Asthma, 2015–2021: The CLEAR Study
Trung N. Tran, Stephanie Chen, Benjamin Emmanuel, et al.
Pragmatic and Observational Research (2025) Vol. Volume 16, pp. 51-66
Open Access
Younger severe asthma patients with interleukin 4 (CC variant) and dupilumab treatment are more likely to achieve clinical remission
Mona Al‐Ahmad, Asmaa Ali, Wafaa Talat
BMC Pulmonary Medicine (2025) Vol. 25, Iss. 1
Open Access
Switching between biologics in severe asthma patients. When the first choice is not proven to be the best
Andriana Ι. Papaioannou, Evangelia Fouka, Despina Papakosta, et al.
Clinical & Experimental Allergy (2020) Vol. 51, Iss. 2, pp. 221-227
Closed Access | Times Cited: 36
Switch from Omalizumab to Benralizumab in Allergic Patients with Severe Eosinophilic Asthma: A Real-Life Experience from Southern Italy
Corrado Pelaia, Claudia Crimi, Santi Nolasco, et al.
Biomedicines (2021) Vol. 9, Iss. 12, pp. 1822-1822
Open Access | Times Cited: 23
Efficacy and Safety of Omalizumab Treatment Over a 16-Year Follow-Up: When a Clinical Trial Meets Real-Life
Francesco Menzella, Matteo Fontana, Marco Contoli, et al.
Journal of Asthma and Allergy (2022) Vol. Volume 15, pp. 505-515
Open Access | Times Cited: 16
Treatment Challenges in Severe Eosinophilic Asthma: Differential Response to Anti-IL-5 and Anti-IL-5R Therapy
Agamemnon Bakakos, Νikoletta Ρovina, Petros Bakakos
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 8, pp. 3969-3969
Open Access | Times Cited: 21
Platelets: a potential role in chronic respiratory diseases?
Mohamad Chebbo, Catherine Duez, Marie‐Christine Alessi, et al.
European Respiratory Review (2021) Vol. 30, Iss. 161, pp. 210062-210062
Open Access | Times Cited: 18
Novel therapeutic approaches targeting endotypes of severe airway disease
Maria De Filippo, Martina Votto, Amelia Licari, et al.
Expert Review of Respiratory Medicine (2021) Vol. 15, Iss. 10, pp. 1303-1316
Closed Access | Times Cited: 17
Switching from one biologic to benralizumab in patients with severe eosinophilic asthma: An ANANKE study post hoc analysis
Cristiano Caruso, Paolo Cameli, Elena Altieri, et al.
Frontiers in Medicine (2022) Vol. 9
Open Access | Times Cited: 11
Comparison between clinical trials and real-world evidence studies on biologics for severe asthma
Francesco Menzella, Andrea Ballarin, Maria Cristina Sartor, et al.
Journal of International Medical Research (2022) Vol. 50, Iss. 11
Open Access | Times Cited: 9
Effectiveness of Dupilumab Treatment to Treat Chronic Rhinosinusitis With Nasal Polyposis: A Systematic Review and Meta-Analysis
Jiyeon Kim, Do Hyun Kim, Se Hwan Hwang
Journal of rhinology (2023) Vol. 30, Iss. 2, pp. 62-68
Open Access | Times Cited: 5
Comparative efficacy of biologics for patients with inadequately controlled asthma: A network meta-analysis
Hayeon Kim, Myeong Gyu Kim, Sung‐Ryeol Kim, et al.
World Allergy Organization Journal (2024) Vol. 17, Iss. 7, pp. 100934-100934
Open Access | Times Cited: 1
Immunobiological therapy in the treatment of severe asthma
David Evangelista Barros de Oliveira, Carlos Gustavo Alves Leitão, F Falcão, et al.
Research Society and Development (2024) Vol. 13, Iss. 5, pp. e14513545933-e14513545933
Open Access
Asthma in the era of SARS CoV-2 virus
Agamemnon Bakakos, Anastasia Krompa
Journal of Asthma (2021) Vol. 59, Iss. 8, pp. 1501-1508
Closed Access | Times Cited: 3
Biologics in severe asthma: Outcomes in clinical trials-Similarities and differences
Agamemnon Bakakos, Νikoletta Ρovina, Stelios Loukides, et al.
Expert Opinion on Biological Therapy (2022) Vol. 22, Iss. 7, pp. 855-870
Closed Access | Times Cited: 2
Saudi Arabian real-life experience with biologic therapy in severe asthma
Safwat Eldaboussi, Ahmed Qabil, Ahmed Lotfi, et al.
Multidisciplinary Respiratory Medicine (2021) Vol. 16
Open Access | Times Cited: 2
Page 1

Scroll to top